Analysts' Top 5 Price Targets of May 26, 2025
Reading Time: 3 minutes
Glaukos Corp. [US3773221029]: Piper Sandler reaffirms Buy rating with a price target of $165 (70% upside potential) Glaukos is a medtech and pharmaceutical company specializing in the development and marketing of innovative therapies for eye diseases, particularly glaucoma, corneal, and retinal disorders. The stock had significantly lost value due to disappointing expectations regarding the new product "iDose.” Nevertheless, Piper Sandler remains optimistic about the long-term potential for iDose and other products in the pipeline. iDose is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
